Weight Loss Drug Acomplia Yanked from Market Over Psychiatric Risks
With the psychiatric side effects of rimonabant (sold as Acomplia in Europe and as Zimulti elsewhere) turning out to be even worse than originally thought, and the effectiveness of this new weight loss drug turning out to be pretty minimal, Sanofi-Aventis has yanked it from the market following a decision by European regulators to suspend marketing approval.